Clinical Pharmacokinetics and Pharmacodynamics of Zolpidem

@article{Salv1995ClinicalPA,
  title={Clinical Pharmacokinetics and Pharmacodynamics of Zolpidem},
  author={Pau Salv{\`a} and Joan Costa},
  journal={Clinical Pharmacokinetics},
  year={1995},
  volume={29},
  pages={142-153}
}
SummaryZolpidem is an imidazopyridine which differs in structure from the benzodiazepines and zopiclone. It is a strong sedative with only minor anxiolytic, myorelaxant and anticonvulsant properties, and has been shown to be effective in inducing and maintaining sleep in adults. The available evidence suggests that zolpidem produces no rebound or withdrawal effects, and patients have experienced good daytime alertness. Zolpidem 10mg in non-elderly and a reduced dose of 5mg in elderly… Expand
Zolpidem for insomnia
TLDR
approved doses of zolpidem are consistently effective in reducing sleep latency and consequently increasing sleep duration in patients with insomnia, however, favorable effects on sleep maintenance are observed less consistently. Expand
Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem
TLDR
The pharmacokinetics and pharmacodynamics of zolpidem were not remarkably affected by itraconazole in healthy volunteers, therefore, unlike triazolam, for example, zol pidem can be used in normal or nearly normal doses together with itraconsazole and probably also with other CYP3A4 inhibitors. Expand
Metabolism of Anxiolytics and Hypnotics: Benzodiazepines, Buspirone, Zoplicone, and Zolpidem
TLDR
Reports to date indicate minimal interactions of zolpidem with coadministered drugs; however, it has been reported to affect the Cmax and clearance of chlorpromazepine and to decrease metabolism of the antiviral agent ritonavin. Expand
Clinically Important Drug Interactions with Zopiclone, Zolpidem and Zaleplon
TLDR
Few clinically important interactions appear to have been reported in the literature with zaleplon, zolpidem and zopiclone, and the fact that these drugs are newer to the market and have not been as extensively studied as the conventional benzodiazepines may be the reason for this. Expand
Pharmacodynamic profile of Zaleplon, a new non‐benzodiazepine hypnotic agent
TLDR
It is shown that zaleplon 10 mg has little or no residual effect when administered in the middle of the night, as late as 1 h before waking, and is devoid of impairment of driving abilities as assessed by actual driving 4’h after dose administration. Expand
Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences.
TLDR
The complete dependence of triazolam clearance on CYP3A activity, as opposed to the mixed CYP participation in zolpidem clearance, may explain the differing sex effects on clearance of the two compounds. Expand
Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration
TLDR
It is confirmed that zolpidem clearance is lower in females than in males, and PD effects of zolPidem from ZST are greater in female subjects, due to a combination of higher plasma concentrations and greater intrinsic sensitivity. Expand
Effects of steady-state clarithromycin on the pharmacokinetics of zolpidem in healthy subjects.
TLDR
The experimental data demonstrate the significant pharmacokinetic interaction between zolpidem and clarithromycin at steady-state and elimination half-life of zolPidem was 1.40-fold longer during co-administration with clarityromycin and its apparent oral clearance was 36.2% lower with claritromycin administration. Expand
Acute neurophysiological effects of the hypnotic zolpidem in healthy volunteers
TLDR
The study with ERPs allows a more direct "moment to moment" investigation of finer mechanisms of changes in cerebral processes underlying the acute ingestion of the drug in question. Expand
Mechanism-Based Pharmacodynamic Modeling of the Interaction of Midazolam, Bretazenil, and Zolpidem with Ethanol
TLDR
The findings of this study show that the pharmacodynamic interactions with a low dose of ethanol in vivo are qualitatively and quantitatively similar for benzodiazepine receptor full agonist, partial agonists, and benzdiazepine BZ1 receptor subtype selective agonists. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 20 REFERENCES
Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential.
TLDR
While zolpidem aids sedation, and may reduce memory or psychomotor function within the first 2 hours after administration of single oral doses, its use as a surgical premedicant remains to be established. Expand
Zolpidem: a nonbenzodiazepine hypnotic for treatment of insomnia.
TLDR
Zolpidem's advantages over benzodiazepines are that it does not lead to tolerance, withdrawal phenomena, or REM rebound; however, for short-term, as-needed use, these advantages are not relevant. Expand
Lack of interaction between zolpidem and H2 antagonists, cimetidine and ranitidine.
TLDR
Zolpidem induced hypnotic effects for the first 3 h which tend to be prolonged by the combination with cimetidine, but psychometric and pharmacokinetic evaluations did not show significant interactions with either anti-H2 receptor agent following zolpide administration. Expand
Enhancement of GABAergic transmission by zolpidem, an imidazopyridine with preferential affinity for type I benzodiazepine receptors.
TLDR
The finding that zolpidem enhanced the function of GABAergic synapses with an efficacy qualitatively and quantitatively different from that of diazepam suggests that this compound is a partial agonist at the benzodiazepine recognition site. Expand
Determination of zolpidem, a new sleep-inducing agent, and its metabolites in biological fluids: pharmacokinetics, drug metabolism and overdosing investigations in humans.
TLDR
The method designed for the investigation of overdose cases is simple and rapid, with good selectivity with respect to commonly prescribed psychotropic drugs, and uses fluorescence detection, which affords high sensitivity and selectivity. Expand
Hypnotic activity of an imidazo-pyridine (zolpidem).
TLDR
Zolpidem is likely to prove useful in the management of transient and short-term insomnia in healthy middle aged individuals when impaired performance the next day is to be avoided. Expand
Dose response effects of zolpidem in normal geriatric subjects.
TLDR
Polysomnographic results showed statistically significant decreases in sleep latency and increases in sleep efficiency at all doses, and subjective reports also showed improved sleep latency, total sleep time, and sleep quality. Expand
Zolpidem-polysomnographic study of the effect of a new hypnotic drug in sleep apnea syndrome
TLDR
A controlled double blind cross-over trial assessed the effects of a single dose of zolpidem 20 mg on nocturnal breathing in patients with mild forms of sleep apnea syndrome and indicated that the drug does not overcome the existing contraindications to the use of hypnotics in this syndrome. Expand
Imidazopyridines as a tool for the characterization of benzodiazepine receptors: A proposal for a pharmacological classification as omega receptor subtypes
TLDR
The nomenclature of a greek letter omega is proposed, as omega 1, omega 2 and omega 3 to designate respectively the central BZ1, BZ2 and the peripheral BZ receptor. Expand
Plasma protein binding of zolpidem in liver and renal insufficiency.
TLDR
Zolpidem binding was studied in plasma from healthy subjects, patients with renal failure, 12 patients with liver cirrhosis and 12 chronic uremics maintained on hemodialysis as well as in 12 serum samples from the placental cord. Expand
...
1
2
...